FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number 3235-0287 Estimated average burden hours per response 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [®] WINGER DENNIS L						2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX]									Relationsh heck all ap X Dire	,		son(s) to 10% C	
(Last)	`	(First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/15/2016											Officer (give title below)		Other below)	(specify
C/O PACIRA PHARMACEUTICALS, INC. 5 SYLVAN WAY, SUITE 300					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									ndividual or Joint/Group Filing (Check Applicable e)				
(Street) PARSIPPANY NJ 07054														Form	Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)																
		Tab	le I - N	lon-Deriv	ative \$	Sec	uritie	s Ac	quired,	Disp	oosed	of, or	Bene	eficia	ally Own	ed			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day					Exec if an	Deemed ecution Date, ny onth/Day/Year)		Code (In	Transaction Dis Code (Instr. and		curities Acquired (/ osed Of (D) (Instr. 3 5)			Secur	ficially d		ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amour	nt (A) or (D)		Price	Repo Trans		(instr	,	(1130.4)
Common Stock 06/15/20					2016	16		Α		1,48	1,488 ⁽¹⁾ A		\$ <mark>0.</mark>	00	6,133		D		
		Та	able II	- Derivat (e.g., p					uired, Di , options	•					y Owned	l			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	on Date,	4. Transac Code (Ir 8)			er ative ities red sed 3, 5)	6. Date Exe Expiration (Month/Day)	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amou or Numt		ount	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	Ov Fo Di or (l) 4)	vnership rrct (D) Indirect (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisable		piration te	Title	of Sha	ares					
Stock Option											11 5 12 0 2 6	Commo		075	• •••••			_	

Explanation of Responses:

\$40.34

1. Represents restricted stock units that vest on June 3, 2017, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

(2)

06/15/2026

2. The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date.

2 975

Remarks:

(Right to

Buy)

/s/ James Scibetta, Attorney-	0.0
in-Fact	<u>0</u> 6

2,975

Stock

\$0.00

<u>06/17/2016</u>

2 975

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/15/2016

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.